Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sjælden dural sinus cavernosus-fistel var årsag til okulomotoriusparese

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pakkeforløb for primær hjernekræft

    Research output: Book/ReportReportCommissioned

View graph of relations

BACKGROUND: As many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nationwide population of glioblastoma patients in Denmark.

METHODS: We included prospectively recorded clinical data from 1364 adult patients with histologically verified glioblastoma from the Danish Neuro-Oncology Registry, 2009-2014.

RESULTS: The age standardized incidence rate was 6.3/100,000 person-years for males and 3.9 for females and the median age was 66 years. The median overall survival was 11.2 months. There was an independently significant prognostic effect of age, performance status, cognitive symptoms, tumor diameter, multifocality, crossing midline, and contrast enhancement. For partial and total resection compared to biopsy only, the adjusted risk of dying was reduced by 43% (HR [CI] 0.57 [0.48-0.68]) and 51% (0.49 [0.40-0.60]), respectively. For patients receiving a partial and full radiochemotherapy regimen compared to no postsurgical treatment, the risk reduction was 56% (HR [CI] 0.44 [0.37-0.53]) and 70% (0.30 [0.25-0.35]), respectively. The full radiochemotherapy regimen was only allocated to 50% of the patients, 29% among the oldest (70+ years) and 60% among the younger (18-69 years).

CONCLUSIONS: Glioblastoma patients had a poor overall survival but with several specific independent prognostic factors. Extensive cancer treatment was associated with an increasing survival in all age groups, but only half of the patients were sufficiently fit for a full regimen of postoperative combined radiochemotherapy.

Original languageEnglish
JournalJournal of Neuro-Oncology
Volume139
Issue number2
Pages (from-to)479-489
Number of pages11
ISSN0167-594X
DOIs
Publication statusPublished - 2018

    Research areas

  • Adolescent, Adult, Aged, Aged, 80 and over, Brain Neoplasms/epidemiology, Chemoradiotherapy/mortality, Combined Modality Therapy, Denmark/epidemiology, Female, Follow-Up Studies, Glioblastoma/epidemiology, Humans, Male, Middle Aged, Neurosurgical Procedures/mortality, Prognosis, Prospective Studies, Registries, Survival Rate, Time Factors, Young Adult

ID: 58154426